

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10758488
Filing Date		2004-01-15
First Named Inventor	Gorenstein	
Art Unit	1635	
Examiner Name	Vivlemore, Tracy Ann	
Attorney Docket Number	UTMB:1019RCE	

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5270163		1993-12-14	GOLD, et al.	
	2	5475096		1995-12-12	GOLD, et al.	
	3	5582981		1996-12-10	TOOLE, et al.	
	4	5639603		1997-06-17	DOWER, et al.	
	5	5663153		1997-09-02	HUTCHERSON, et al.	
	6	5668265		1997-09-16	NADEAU, et al.	
	7	5670637		1997-09-23	GOLD, et al.	
	8	5696249		1997-12-09	GOLD, et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10758488
Filing Date		2004-01-15
First Named Inventor	Gorenstein	
Art Unit	1635	
Examiner Name	Vivlemore, Tracy Ann	
Attorney Docket Number	UTMB:1019RCE	

	9	5756291		1998-05-26	GRIFFIN, et al.	
	10	5844106		1998-12-01	SEELA, et al.	
	11	6171792	B2	2001-01-09	BRENT, et al.	
	12	6180348	B1	2001-01-30	LI	
	13	6346611	B1	2002-02-12	PAGRATIS, et al.	
	14	6369208	B1	2002-04-09	COLE, et al.	
	15	6514948	B1	2003-02-04	RAZ, et al.	
	16	6551795	B1	2003-04-22	RUBENFIELD, et al.	
	17	6610504	B1	2003-08-26	YUAN	
	18	6713616	B2	2004-03-30	PAGRATIS, et al.	
	19	6716629	B1	2004-04-06	HESS, et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10758488
Filing Date	2004-01-15
First Named Inventor	Gorenstein
Art Unit	1635
Examiner Name	Vivlemore, Tracy Ann
Attorney Docket Number	UTMB:1019RCE

	20	6867289	B1	2005-03-15	GORENSTEIN, et al.	
--	----	---------	----	------------	--------------------	--

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20010014461	A1	2001-08-16	HUTCHENS, et al.	
	2	20010014479	A1	2001-08-16	HUTCHENS, et al.	
	3	20010034330	A1	2001-10-25	KENSIL	
	4	20030133229	A1	2003-07-31	KLINMAN, et al.	
	5	20030162190	A1	2003-08-28	GORENSTEIN, et al.	
	6	20030162216	A1	2003-08-28	GOLD, et al.	
	7	20030186906	A1	2003-10-02	SCHLINGENSIEPEN, et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS

Remove

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10758488
Filing Date	2004-01-15
First Named Inventor	Gorenstein
Art Unit	1635
Examiner Name	Vivemore, Tracy Ann
Attorney Docket Number	UTMB:1019RCE

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	0 855 184	EP	A1	1998-07-29	LIPFORD, et al.		<input type="checkbox"/>
	2	99/54506	WO	A1	1999-10-28	LI		<input type="checkbox"/>
	3	00/24404	WO	A1	2000-05-04	GORENSTEIN, et al.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add](#)

NON-PATENT LITERATURE DOCUMENTS

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	AMARZGUIOUI, M., et al., Nuc Acids Res, 31, 589-595, (2003) – Tolerance for mutations and chemical modifications in a siRNA	<input type="checkbox"/>
	2	ANDREOLA, M., et al., "Towards the Selection of Phosphorothioate Aptamers: Optimizing In Vitro Selection Steps with Phosphorothioate Nucleotides," European Journal of Biochemistry 267:5032-5040	<input type="checkbox"/>
	3	BRAASCH, D.A., et al., Nucleic Acids Res, 30(23), 5160-7 (2002) -Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design	<input type="checkbox"/>
	4	BRAASCH, D.A. AND D.R. COREY, Biochemistry, 41, 4503-4510 (2002) - Novel antisense and peptide nucleic acid strategies for controlling gene expression	<input type="checkbox"/>
	5	CAPLEN, N.J., et al., PNAS, 98, 9742-9747 (2001) – Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10758488
Filing Date	2004-01-15
First Named Inventor	Gorenstein
Art Unit	1635
Examiner Name	Vivlemore, Tracy Ann
Attorney Docket Number	UTMB:1019RCE

6	CASSIDAY, L., et al., "In Vivo Recognition of an RNA Aptamer by its Transcription Factor Target," Biochemistry (2001), 40:2433-3438	<input type="checkbox"/>
7	CHI, J.T., PNAS, 100(11), 6343-6 (2003) - Genomewide view of gene silencing by small interfering RNAs.	<input type="checkbox"/>
8	ELBASHIR, et al., "RNA Interference is Mediated by 21- and 22- nucleotide RNAs," Genes and Development (2001), 15:188-200	<input type="checkbox"/>
9	ELGEMEIE, "Thioguanine, Mercaptoputine: Their Analogs and Nucleosides as antimetabolites," Current Pharmaceutical Design (2003), 9:2627-2642	<input type="checkbox"/>
10	FIRE, et al., Nature, 391, 806 (1998) – Potent and specific genetic interference by dsRNA in C.elegans	<input type="checkbox"/>
11	GITLIN, L., et al., Nature, 418, 430-434 (2002) – Short interfering RNA confers intracellular antiviral immunity in human cells.	<input type="checkbox"/>
12	HU, W., et al., Curr Biol, 12, 1301-1311 (2002) – Inhibition of retroviral pathogenesis by RNA interference.	<input type="checkbox"/>
13	JACKSON, A.L., et al., Nat Biotech, 21(6), 635-637 (2003) – Expression profiling reveals off-target gene regulation by RNAi.	<input type="checkbox"/>
14	JACQUE, J.M., et al., Nature, 418, 435-438 (2002) – Modulation of HIV-1 replication by RNA interference.	<input type="checkbox"/>
15	JANSEN, B. AND U. ZANGEMEISTER-WITTE, Lancet Oncol, 3, 672-683 (2002) – Antisense therapy for cancer--the time of truth.	<input type="checkbox"/>
16	KANAORI, et al., "Effect of Phosphorothioate Chirality on i-Motif Structure and Stability," Biochemistry (2004), 43:5672-5679	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10758488
Filing Date		2004-01-15
First Named Inventor	Gorenstein	
Art Unit	1635	
Examiner Name	Vivlemore, Tracy Ann	
Attorney Docket Number	UTMB:1019RCE	

17	KAWASAKI, H., et al (Taira), Nuc Acids Res, 31(3), 981-987 (2003) – siRNAs generated by recombinant human Dicer include specific and significant but target site-independent gene silencing in human cells.	<input type="checkbox"/>
18	KING, D. et al., "Combinatorial Selection and Binding of Phosphorothioate Aptamers Targeting Human NF-kappa B RelA (p65) and p50," Biochemistry (2002), 41:9696-9706	<input type="checkbox"/>
19	KING, D.J., "Selection, Binding and Design of Phosphorothioate Duplex Aptamers for the Transcription Factors NF-IL6 and NP-KB," dissertation August 2001	<input type="checkbox"/>
20	KOLLER, E., et al., Trends Pharm Sci, 21, 142-148 – Elucidating cell signaling mechanisms using antisense technology.	<input type="checkbox"/>
21	LESCAR, J., et al., Cell 105(1), 137-48. (2001) - The fusion glycoprotein shell of Semliki Forest virus: an icosahedral assembly primed for fusogenic activation at endosomal pH.	<input type="checkbox"/>
22	MCCAFFREY, A.P., et al., Nat Biotechnol, 21(6), 639-44 (2003) - Inhibition of hepatitis B virus in mice by RNA interference	<input type="checkbox"/>
23	MILLER, V.M., et al., PNAS, 100(12), 7195-200 - Allele-specific silencing of dominant disease genes	<input type="checkbox"/>
24	NOVINA, C.D., et al., Nat Med, 8, 681-686 (2002) – siRNA-directed inhibition of HIV-1 infection	<input type="checkbox"/>
25	PLETNEV, S.V., et al., Cell 105(1), 127-36 (2001) - Locations of carbohydrate sites on alphavirus glycoproteins show that E1 forms an icosahedral scaffold.	<input type="checkbox"/>
26	RAVEH, S., "Peptidic Determinants and Structural Model of Human NDP kinase B Bound in Single-Stranded DNA," Biochemistry (2001), 40:5882-5893	<input type="checkbox"/>
27	SAZANI, et al., "Nuclear Antisense Effects of Neutral Anionic and Cationic Oligonucleotide Analogs," Nucleic Acids Research (2001), 29:3965-3974	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10758488
Filing Date	2004-01-15
First Named Inventor	Gorenstein
Art Unit	1635
Examiner Name	Vivlenmore, Tracy Ann
Attorney Docket Number	UTMB:1019RCE

28	SEMIZAROV, D., et al., PNAS, 100(11), 6347-52 (2003) - Specificity of short interfering RNA determined through gene expression signatures.	<input type="checkbox"/>
29	SONG, E., et al., Nat Med, 9, 347-351 (2003) – RNA interference targeting Fas protects mice from fulminant hepatitis.	<input type="checkbox"/>
30	SONG, E., et al., J Virol. 2003 Jul;77(13):7174-81 (2003) - Sustained small interfering RNA-mediated Human Immunodeficiency Virus Type 1 inhibition in primary macrophages.	<input type="checkbox"/>
31	UEDA, TAKUYA, et al. (1991) Phosphorothioate-containing RNAs show mRNA activity in the prokaryotic translation systems in vitro. Nucleic Acids Research, Vol. 19, No. 3, pp. 547-552.	<input type="checkbox"/>
32	XIA, H.B. et al. Nat Biotech, 20, 1006-1010 (2002) – siRNA-mediated gene silencing in vitro and in vivo.	<input type="checkbox"/>
33	YANG, X., et al., "Construction and Selection of Bead-Bound Combinatorial Oligonucleoside Phosphorothioate and Phosphorodithioate Aptamer Libraries Designed for Rapid PCR-Based Sequencing," Nucleic Acid Research (2002), 30:132-140	<input type="checkbox"/>
34	YOKOTA, T., et al. (Taira), EMBO Rep., 4(6), 602-608 (2003) – Inhibition of intracellular hepatitis C virus by synthetic and vector-derived small interfering RNAs.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10758488
Filing Date	2004-01-15
First Named Inventor	Gorenstein
Art Unit	1635
Examiner Name	Vivlemore, Tracy Ann
Attorney Docket Number	UTMB:1019RCE

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/chaaney singleton/	Date (YYYY-MM-DD)	2007-08-22
Name/Print	Chaaney P. Singleton	Registration Number	53598

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.